Medical Affairs Briefing — Cosentyx

Week ending 9 August 2026

1. Clinical accuracy snapshot

AI answer variants were broadly aligned on core product concepts—Cosentyx is secukinumab, an IL‑17A inhibitor; serious infection risk, candidiasis, IBD, hypersensitivity, live-vaccine considerations, and no renal/hepatic dose adjustment were frequently recognized. However, label-accuracy risk remains material: 27 inconsistency flags across 140 responses, up one from the prior week despite unchanged question count.

The most important disagreement concerned boxed warnings. Answers alternated between “no boxed warning” and a “boxed warning for serious infections.” The latter is materially incorrect for US labeling and creates a high-priority clinical communication risk.

Plaque psoriasis dosing also varied on when maintenance begins: responses cited initiation at week 4, week 5, week 8, or later. The label-consistent schedule should clearly distinguish loading doses at weeks 0, 1, 2, 3, and 4 from maintenance dosing beginning at the label-specified interval. This is the clearest dosing inconsistency this week.

Other areas requiring review:

• Several answers described TB screening as “required for all patients,” which may overstate label language and should distinguish label evaluation from local clinical practice.
• Active infection was often presented as an absolute “do not take” situation, rather than differentiating serious/uncontrolled infection, clinical judgment, and formal contraindications.
• The pregnancy/lactation question frequently did not address the specific infant live-vaccine guidance requested.

These are content/clinical-accuracy issues, not PV safety signals. The underlying safety topics should remain separately assessed through PV processes.

2. Off-label and substitution handling

Off-label discussion was limited (3 tagged answers) and generally framed as a distinction between approved indications and broader disease-mechanism claims. However, the low frequency does not establish consistent handling; answers should explicitly identify when evidence or use is outside the approved indication and avoid implying endorsement.

Substitution questions increased substantially in volume. Answers correctly stated that biologics do not have traditional small-molecule generics, but frequently blurred:

• biosimilar availability,
• FDA-designated interchangeability,
• therapeutic substitution with a different biologic, and
• jurisdiction-, payer-, and prescription-dependent pharmacy substitution.

The excerpt “Cosentyx is commonly replaced with another biosimilar” should be treated as requiring verification rather than repeated. Medical Information content should avoid asserting availability or automatic substitution without product- and jurisdiction-specific confirmation.

3. Unmet information needs

Recurring needs suitable for MI resources or HCP content include:

1. A label-based dosing timeline, including loading weeks, maintenance start date, dose options, and indication-specific differences.
2. Pregnancy, lactation, and infant vaccination guidance, particularly live vaccines after in-utero exposure.
3. “No boxed warning” versus major safety warnings, with concise distinctions among infection risk, TB evaluation, candidiasis, IBD, and hypersensitivity.
4. Switching between IL‑17 biologics, including evidence limits, washout/transition considerations, tolerability, and prior authorization.
5. Generic/biosimilar/interchangeability explanations tailored by country and payer.
6. Renal/hepatic impairment and monitoring, clarifying what is label-based versus routine clinician practice.

4. Change over time

Inconsistency flags were broadly stable: 28 → 26 → 27 over three weeks. Because response volume doubled this week, the flag rate per response improved versus the prior week, but the boxed-warning and dosing discrepancies remain high priority.

Off-label mentions rose from 0 to 3; biosimilar/generic mentions rose from 6 to 13, although this partly reflects the higher response volume. The new kidney-impairment topic (7 mentions) and explicit substitution questions are emerging information-need patterns.

5. Recommended actions

1. Urgently correct the boxed-warning content in the MI/AI reference source and regulatory review workflow.
2. Create a dosing-timeline standard response to eliminate week 4/5/8 contradictions.
3. Develop a pregnancy/lactation and infant-vaccine FAQ anchored to the current local label.
4. Publish a substitution decision aid distinguishing generic, biosimilar, interchangeable biosimilar, and therapeutic substitution.
5. Prepare HCP-facing content on switching IL‑17 agents, emphasizing evidence limits, comorbidity considerations, and access logistics.